Skip to main content
Skip to footer
Home
Triverity
Education
Acute infection & sepsis
Immune Response
Machine Learning
Advocacy
Evidence
Publications
Abstracts
Pipeline
News
News
Press Release
ML Blogs
Podcasts
Media contact
Careers
About
Leadership
Investors
Partner with us
Awards
Certificates
Reach out
Home
Triverity
Education
Acute infection & sepsis
Immune Response
Machine Learning
Advocacy
Evidence
Publications
Abstracts
Pipeline
News
News
Press Release
ML Blogs
Podcasts
Media contact
Careers
About
Leadership
Investors
Partner with us
Awards
Certificates
Reach out
Reach out
Author:
Pedro Colmenarez
International multi-cohort analysis identifies novel framework for quantifying immune dysregulation in critical illness: results of the SUBSPACE consortium
May 8, 2025
Moore, A. et al. bioRxiv. Nov 2024. Pre-Print
FDA clears acute infection and sepsis test
May 6, 2025
Recognizing It Early While Getting It Right: The Value of Novel Sepsis Testing Tools
April 2, 2025
Inflammatix Ships TriVerity™ Test Cartridges and Myrna™ Instruments to the U.S. Military
March 25, 2025
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for…
A better, faster sepsis test that can save lives
February 6, 2025
Inflammatix Gets FDA Clearance for 30-Minute Sepsis Test, Preps for US Launch
January 21, 2025
Inflammatix Scores FDA Approval for Precision Infection Test
January 21, 2025
Inflammatix Receives FDA Clearance for First-in-Class TriVerity™ Test
January 21, 2025
Inflammatix begins trial evaluating mRNA test for patient infection status
November 12, 2024
Inflammatix Initiates TriVerity™ for Improved Management of Emergency Department Patients with Suspected Infections (TIMED) Trial
November 11, 2024
First interventional study designed to demonstrate the clinical utility of the TriVerity test and its impact on patient management Sunnyvale,…
1
2
3
…
10
→